|
Exploratory Development
(Post discovery through Phase II) |
Full Development
(Registrational program) |
Marketed Product Development
(Approved in at least one major market) |
| Anti-Fucosyl GM1 (oncology) |
Nivolumab (Anti-PD1)
(oncology) |
YERVOY® (ipilimumab) (oncology) |
| JAK2 Inhibitor (oncology) |
Elotuzumab
(oncology) |
SPRYCEL® (dasatinib) (oncology) |
| IL-21 (oncology) |
Metreleptin
(metabolics) |
ERBITUX® (cetuximab) (oncology) |
| Lirilumab (Anti-KIR) (oncology) |
Daclatasvir (NS5A inhibitor)
(virology) |
FORXIGA™** (dapagliflozin) (metabolics) |
| Urelumab (Anti-CD137) (oncology) |
Asunaprevir (NS3 inhibitor)
(virology) |
ONGLYZA® (saxagliptin)
KOMBIGLYZE XR™ (saxagliptin and metformin HCL extended-release) (metabolics) |
| Notch Inhibitors (oncology) |
Peginterferon lambda-1a
(virology) |
SYMLIN® (pramlintide acetate) injection (metabolics) |
| Anti-CXCR4 (oncology) |
|
BYETTA® (exenatide) injection(metabolics)
BYDUREON® (exenatide extended-release for injectable suspension) (metabolics) |
| Anti-LAG3 (oncology) |
|
ORENCIA® (abatacept)
(immunology) |
GPR119 Agonist
(metabolics) |
|
NULOJIX® (belatacept) (immunology) |
| PEG-FGF21 (metabolics) |
|
ELIQUIS® (apixaban)
(cardiovascular) |
| 11βHSD Inhibitor (metabolics) |
|
BARACLUDE® (entecavir)
(virology) |
| GPR40 Agonist (metabolics) |
|
REYATAZ® (atazanavir sulfate) (virology) |
| Anti-CD40L (immunology) |
|
SUSTIVA® (efavirenz)
ATRIPLA® (efavirenz / emtricitabine / tenofovir disoproxil fumarate) (virology)
|
| Anti-CD40 (immunology) |
|
**FORXIGA is not approved in the U.S.
|
| Anti-CD28 (immunology) |
|
| Anti-IL31 (immunology) |
|
| Anti-IP10 (immunology) |
|
|
| IL-17/IL-23 biAb (immunology) |
|
|
| S1P1 Modulator (immunology) |
|
|
| LPA1 Antagonist (immunology) |
|
|
| CCR1 Antagonists (immunology) |
|
|
| Clazakizumab (Anti-IL6) (immunology) |
|
|
| LXR Modulators (cardiovascular) |
|
|
| PCSK9 Adnectin (cardiovascular) |
|
|
| CCR2 / 5 Antagonists (cardiovascular) |
|
|
| IKur Antagonists (cardiovascular) |
|
|
| Factor XIa Inhibitor (Parenteral) (cardiovascular) |
|
|
| Factor XIa Inhibitor (Oral) (cardiovascular) |
|
|
| PEG-Relaxin (cardiovascular) |
|
|
| HIV Attachment Inhibitor (virology) |
|
|
| NRT Inhibitor (virology) |
|
|
| HIV Maturation Inhibitor (virology) |
|
|
| Anti-PD-L1 (virology) |
|
|
| NS5B Non Nuc (virology) |
|
|
| α-7 Nicotinic Agonist (neuroscience) |
|
|
| Gamma Secretase Modulator (neuroscience) |
|
|
| Triple Reuptake Inhibitor (neuroscience) |
|
|
| Microtubule Stabilizer (neuroscience) |
|
|
| Myostatin Adnectin (neuroscience) |
|
|
|
|
|
|
|
|
|
|
|
|